NRx Pharmaceuticals disputes Kadima claims amid arbitration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St futures ease as Big Tech earnings rekindle AI spending worries, oil jumps
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits fresh 40-year high versus yen, edges higher against euro
NRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute
June 25, 2026 4:01 PM EDTWILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (NRx or the Company) today issued the following statement in response to recent public claims made by Kadima Neuropsychiatry Institute (Kadima).
Kadima issued a public statement on June 24, 2026 making a series of unfounded allegations related to the non-acquisition of Kadima by HOPE Therapeutics, Inc., a majority-owned subsidiary of the Company (HOPE). As disclosed in recent filings with the Securities and Exchange Commission (the SEC), NRx has compelled arbitration with Kadima over Kadimas failure to meet key closing conditions contemplated in the related transaction... More
